Put Options

17 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$56.16 - $60.96 $44,928 - $48,768
800 Added 16.67%
5,600 $339,000
Q2 2024

Aug 14, 2024

BUY
$53.58 - $57.02 $42,864 - $45,616
800 Added 20.0%
4,800 $269,000
Q1 2024

May 01, 2024

BUY
$42.56 - $59.82 $21,280 - $29,910
500 Added 14.29%
4,000 $225,000
Q4 2023

Feb 12, 2024

SELL
$32.18 - $46.57 $312,146 - $451,729
-9,700 Reduced 73.48%
3,500 $157,000
Q3 2023

Nov 13, 2023

BUY
$44.2 - $50.2 $123,760 - $140,560
2,800 Added 26.92%
13,200 $600,000
Q2 2023

Aug 10, 2023

BUY
$31.86 - $67.26 $6,372 - $13,452
200 Added 1.96%
10,400 $450,000
Q1 2023

May 09, 2023

BUY
$45.44 - $74.26 $386,240 - $631,210
8,500 Added 500.0%
10,200 $670,000
Q4 2022

Feb 10, 2023

SELL
$41.39 - $81.0 $389,066 - $761,400
-9,400 Reduced 84.68%
1,700 $76,000
Q3 2022

Nov 10, 2022

BUY
$72.36 - $113.1 $130,248 - $203,580
1,800 Added 19.35%
11,100 $803,000
Q2 2022

Aug 15, 2022

SELL
$87.2 - $114.05 $3.19 Million - $4.17 Million
-36,600 Reduced 79.74%
9,300 $998,000
Q1 2022

May 13, 2022

SELL
$94.19 - $124.49 $1.3 Million - $1.72 Million
-13,800 Reduced 23.12%
45,900 $5.09 Million
Q4 2021

Feb 11, 2022

SELL
$119.57 - $139.07 $848,947 - $987,397
-7,100 Reduced 10.63%
59,700 $7.64 Million
Q3 2021

Nov 15, 2021

BUY
$109.17 - $142.35 $6.17 Million - $8.04 Million
56,500 Added 548.54%
66,800 $8.89 Million
Q2 2021

Aug 16, 2021

SELL
$100.34 - $115.69 $110,374 - $127,259
-1,100 Reduced 9.65%
10,300 $1.11 Million
Q1 2021

May 17, 2021

BUY
$101.51 - $125.27 $162,416 - $200,432
1,600 Added 16.33%
11,400 $1.2 Million
Q4 2020

Feb 16, 2021

BUY
$85.88 - $105.36 $506,692 - $621,624
5,900 Added 151.28%
9,800 $1.02 Million
Q3 2020

Nov 16, 2020

BUY
$72.74 - $92.5 $283,686 - $360,750
3,900 New
3,900 $334,000

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $10.6B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Capstone Investment Advisors, LLC Portfolio

Follow Capstone Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.